What Is Neurology? Clinical Scope, Research, and Training

Last verified: October 3, 2026. Neurology is the medical specialty devoted to diagnosing and treating disorders of the nervous system: the brain, spinal cord, peripheral nerves, the junctions where nerves meet muscle, and the muscles themselves. It is a clinical discipline first, a doctor’s specialty with patients, examinations, and treatment decisions, and it also has a large research enterprise built around the diseases it treats. This page explains what neurology covers, how it differs from neuroscience and psychiatry, how clinical research in neurology is organized and funded, and how people train into the field. It is an educational overview of a research and professional field, not medical advice.

What Is Neurology?

A neurologist is a physician who specializes in disorders of the nervous system. The conditions they manage range from common problems such as headache and epilepsy, through stroke, dementia, and Parkinson disease, to rarer neuromuscular and inherited conditions. The defining skill of the specialty is localization: working out, from a patient’s history and a structured examination of mental status, cranial nerves, strength, reflexes, sensation, coordination, and gait, where in the nervous system a problem lies, and then deciding what could be causing it. Imaging, electrical recordings, spinal fluid analysis, and genetic and laboratory testing are then used to confirm or refine that reasoning.

Neurology is a medical specialty in the same sense as cardiology or endocrinology (compare what endocrinology is), organized around an organ system and the patients who have diseases of it. That distinguishes it from the laboratory sciences that study the same organ without treating anyone.

Neurology vs. Neuroscience vs. Psychiatry

These three fields share a subject, the brain and nervous system, and are constantly confused with one another. The practical difference is in what each one is organized around.

• Neurology is a clinical specialty. Its core unit is the patient with a disease of the nervous system, and its core activities are diagnosis, treatment, and the clinical research that tests new treatments. Neurologists are physicians.
• Neuroscience is a broad research field spanning molecular, cellular, systems, cognitive, and computational study of the nervous system in health as well as disease. Its practitioners are mostly research scientists, and many hold no medical degree. See What Is Neuroscience? and the narrower What Is Neurobiology?
• Psychiatry is the medical specialty for mental, emotional, and behavioral disorders. The boundary with neurology has always been porous (dementia, epilepsy-related behavior change, and movement disorders sit on the border), and the two specialties have shared roots, but in modern practice they are separate training tracks and separate board certifications. See What Is Psychiatry?

A useful rule of thumb: neuroscience asks how the nervous system works, neurology asks what has gone wrong with it in a given patient and what to do about it, and psychiatry asks the same of mental illness. In practice the three feed each other. A discovery about how a gene affects neurons (neuroscience) can become a diagnostic test or drug target that neurologists test in trials, and the trial results then raise new laboratory questions. This loop is usually called translational research, and it is the reason a research-administration audience meets neurology so often. The overlapping work lands on the same grant mechanisms, compliance offices, and data-sharing policies.

Neurology also borders psychology (see What Is Psychology?) through neuropsychology, the assessment of cognition and behavior in people with brain disease, which is typically performed by clinical psychologists working alongside neurologists.

What Neurologists Treat

The disease areas below are the ones most often used to organize neurological practice and research. This is a map of the field, not a clinical reference.

• Cerebrovascular disease (stroke). Disorders of blood supply to the brain, including ischemic and hemorrhagic stroke, and the emergency and rehabilitation care around them.
• Epilepsy and seizure disorders. Conditions marked by recurrent seizures, with an associated body of work on electroencephalography (EEG), medication, surgery, and devices.
• Neurodegenerative disease and dementia. Alzheimer disease and other dementias, Parkinson disease and related movement disorders, amyotrophic lateral sclerosis (ALS), and Huntington disease.
• Neuroimmunology and demyelinating disease. Multiple sclerosis and related autoimmune conditions of the nervous system.
• Headache medicine. Migraine and other primary and secondary headache disorders.
• Neuromuscular disease. Disorders of peripheral nerve, neuromuscular junction, and muscle, such as neuropathies and myasthenia gravis.
• Neurocritical care and neurotrauma. Brain and spinal cord injury and the intensive care of severe neurological illness.
• Sleep medicine, neuro-oncology, neuro-infectious disease, and child neurology. Each has its own clinical and research community, and child neurology is a distinct training pathway covering neurological disease from infancy through adolescence.

Many of these areas are also recognized as formal subspecialties with additional fellowship training after residency. The exact list of certifiable subspecialties is set by certifying bodies and changes over time, so check the American Board of Psychiatry and Neurology (ABPN) for the current list rather than relying on any secondary summary.

Tools and Methods in Neurology

Neurological diagnosis and research rely on a toolkit that is partly bedside and partly technological.

• The neurological examination. A standardized bedside assessment that remains the starting point of every evaluation.
• Structural and functional imaging. Computed tomography (CT) and magnetic resonance imaging (MRI) show structure and many pathologies, while positron emission tomography (PET) and functional MRI measure metabolism, receptor binding, or blood-flow-related activity. Image sharing and analysis in research settings raise their own data-management questions; see OpenNeuro and BIDS neuroimaging data sharing.
• Electrophysiology. EEG records the brain’s electrical activity, and nerve conduction studies and electromyography test peripheral nerves and muscle. The first recordings of human brain electrical activity date from the 1920s.
• Cerebrospinal fluid and blood biomarkers. Laboratory measures that support diagnosis or serve as outcome measures in trials, an area in which research is moving quickly for several neurodegenerative diseases.
• Genetic testing. Used for inherited neurological disease and increasingly as an enrollment criterion in trials. For the broader field, see What Is Genomics?
• Standardized rating scales and cognitive tests. Because many neurological outcomes are functional rather than a single lab value, the field depends on validated scales. Examples are covered below and in this site’s guides to the NIH Stroke Scale, the Cincinnati Prehospital Stroke Scale, and the Montreal Cognitive Assessment.

A Short History

The word “neurology” is generally traced to the 17th-century English physician Thomas Willis, whose 1664 work on the anatomy of the brain and nerves gave the study of the nervous system its name. Neurology emerged as a separate clinical discipline in the 19th century, and Jean-Martin Charcot, working at the Salpetriere hospital in Paris, is widely regarded as a founder of modern clinical neurology for his systematic correlation of bedside findings with later anatomical findings. In English-speaking medicine, John Hughlings Jackson’s work on epilepsy and the organization of the nervous system was similarly influential.

The 20th century added electroencephalography, then CT and MRI, which let clinicians see the brain in living patients, and a growing set of effective treatments. Professional organization followed: the American Academy of Neurology (AAN) was founded in 1948. In the United States, the federal institute dedicated to neurological research was established by Public Law 81-692, signed on August 15, 1950, as the National Institute of Neurological Diseases and Blindness. It has been renamed several times and has been the National Institute of Neurological Disorders and Stroke (NINDS) since 1988.

Clinical trials changed the field in the decades after. A landmark example is the NINDS rt-PA Stroke Study, published in 1995, which tested intravenous tissue plasminogen activator for acute ischemic stroke and became a foundation for emergency stroke treatment. Later trials of mechanical clot retrieval, reported from 2015 onward, extended acute stroke care further. Both are reminders that neurology’s treatment advances are tied directly to the design and funding of large randomized trials.

Clinical Research and Trials in Neurology

Neurology is one of the most trial-intensive specialties, and it has distinctive methodological challenges. The nervous system is hard to sample directly, many diseases progress slowly over years, and outcomes are often functional, such as walking, speaking, thinking, or independence, rather than a blood test.

NINDS and the Networks It Funds

NINDS, part of the National Institutes of Health (NIH), is the principal US federal funder of research on neurological disease. Beyond investigator-initiated grants, it has built dedicated clinical trial infrastructure. Publicly described NINDS-supported networks include:

• NIH StrokeNet, established in 2013, which supports stroke prevention, treatment, and recovery trials from early-phase work through phase III.
• NeuroNEXT, established in 2011, designed to run early-phase trials and biomarker studies in neurological disorders efficiently.
• NETT (Neurological Emergencies Treatment Trials), which began in 2007 and conducts phase III trials in emergency neurology.
• SIREN (Strategies to Innovate EmeRgENcy Care Clinical Trials Network), which runs trials across neurological, cardiac, respiratory, hematologic, and trauma emergencies, including conditions such as status epilepticus and traumatic brain injury.

These networks share common infrastructure, such as a central institutional review board, master trial agreements, and common data elements. That infrastructure exists to cut start-up time, which is usually the largest administrative cost in multi-site trials. NINDS also publishes Common Data Elements (CDEs), recommended standardized definitions and instruments for collecting data in specific neurological conditions, so that results from different studies can be compared and pooled. For the funding side, see how paylines work in the glossary entry on the NINDS payline, and the U01 cooperative agreement mechanism that NIH commonly uses for multi-site clinical research.

Endpoints and Outcome Measures

An endpoint is the outcome a trial is designed to measure. The choice of endpoint is the most consequential design decision in a neurological trial, because it determines what “working” means. Commonly used instruments, by condition, include the following. Which instrument a trial uses, and in what form, is always set out in its protocol, and the list below is illustrative rather than a standard.

• Stroke. The NIH Stroke Scale (NIHSS) rates neurological deficit at the bedside, and the modified Rankin Scale (mRS) is a widely used measure of disability or dependence after stroke, scored from 0 to 6. Trials often report the proportion of patients reaching a defined mRS level at a fixed follow-up time.
• Multiple sclerosis. The Expanded Disability Status Scale (EDSS), together with relapse rates and MRI lesion measures.
• Parkinson disease. The Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS).
• Amyotrophic lateral sclerosis. The ALS Functional Rating Scale-Revised (ALSFRS-R), alongside survival.
• Alzheimer disease and dementia. Cognitive and functional composites such as the Clinical Dementia Rating Sum of Boxes (CDR-SB), with screening tools such as the MoCA used for case-finding rather than as a trial outcome.
• Epilepsy. Seizure frequency, typically from patient diaries, and seizure freedom over a defined period.

Two recurring problems are worth knowing. First, many of these scales are clinician-rated and depend on rater training and certification, which is why large trials certify their raters. Second, a trial can show a statistically significant change on a scale without a change that matters to patients, so questions of minimal clinically important difference and of surrogate versus clinical endpoints are central to how neurological results are interpreted and approved.

Design, Oversight, and Transparency

Most confirmatory neurological trials are randomized, controlled, and blinded where possible; see phase 2 and phase 3 trials for how development stages are defined. Because many neurological conditions affect decision-making capacity, informed consent is especially important and sometimes complicated. Trials in dementia or in acute stroke, for example, must address consent from a legally authorized representative or, in emergencies, the regulatory pathways that exist for exception from informed consent. See informed consent and the role of the institutional review board. Trials are registered and results reported under the transparency rules summarized at ClinicalTrials.gov and clinical trial transparency, and prespecified analysis is documented in a statistical analysis plan.

Who Funds Neurological Research

• NINDS is the lead NIH institute for neurological disease. Other NIH institutes fund the disease areas that fall within their missions, notably the National Institute on Aging for Alzheimer disease and related dementias, and the National Institute of Mental Health for the psychiatric end of the spectrum.
• The NIH BRAIN Initiative is a cross-institute program funding new tools for studying brain circuits, with downstream relevance to neurological disease.
• The US Department of Defense funds neurotrauma and related research through its congressionally directed medical research programs.
• Disease foundations and charities are major funders in neurology, including organizations focused on Parkinson disease, Alzheimer disease, multiple sclerosis, epilepsy, and ALS. See disease charity research funding.
• Non-US public funders such as the UK’s Medical Research Council and the Wellcome Trust (a charitable foundation) support neurological research in the UK and internationally.
• Industry sponsors pay for most late-stage drug and device trials, which adds sponsor-investigator contracting and budgeting to the administrative picture.

For career-stage funding, see NIH career development K awards and the comparison K08 vs. K23, the two mechanisms physician-scientists in neurology most often weigh.

Journals and Professional Societies

Major clinical journals in the field include Neurology (the journal of the American Academy of Neurology), Annals of Neurology, JAMA Neurology, The Lancet Neurology, Brain, and Nature Reviews Neurology. Disease-specific journals cover epilepsy, stroke, movement disorders, and multiple sclerosis individually.

Among professional societies, the American Academy of Neurology (founded 1948) is the largest in the United States, and the American Neurological Association focuses on academic neurology. Child neurology has its own society, and the World Federation of Neurology and the European Academy of Neurology serve international membership. Disease-specific societies exist for most major conditions. Membership and annual meetings are where much of the field’s clinical guidance and research is presented.

Training and Career Paths

In the United States, becoming a neurologist means completing medical school (MD or DO), then residency. For board certification through the ABPN, the applicant needs an ACGME-accredited first postgraduate year, usually with at least six months of internal medicine, followed by three years of neurology residency in an accredited program, or an integrated four-year program that includes the first year. Fellowship training of one or more additional years leads to subspecialty practice, for example in epilepsy, vascular neurology, or neuromuscular medicine. Child neurology follows its own pathway. Requirements differ in other countries, and specific requirements change, so confirm them against the ABPN or the relevant national body.

Not everyone in neurology research is a clinician. Neurologists who also run research programs are physician-scientists, often supported by K awards; PhD scientists in neuroscience, genetics, biostatistics, and bioengineering are essential members of the research teams; and clinical research coordinators, data managers, and regulatory staff run the trials. For the broader landscape of scientific fields, see branches of science.

Neurology and Research Administration

For research administrators, neurology is a recurring and demanding case. A single neurological trial network may touch an NIH cooperative agreement, a central IRB, master clinical trial agreements, industry-sponsored arms, imaging and biospecimen repositories, genomic data governed by controlled-access rules, and a registration and results-reporting obligation. Consent questions around capacity, device and drug regulation, and long follow-up periods add compliance weight. Understanding the vocabulary (endpoints, rater certification, common data elements, network infrastructure) makes it much easier to budget, negotiate, and support these studies accurately.

Frequently Asked Questions

What is the difference between a neurologist and a neurosurgeon?

A neurologist is a physician who diagnoses and medically manages nervous system disorders. A neurosurgeon is a surgeon who operates on the brain, spine, and nerves. They train in separate residencies and often work together on the same patients, for example in tumor, epilepsy surgery, and stroke care.

Is neurology the same as neuroscience?

No. Neurology is a clinical medical specialty that treats patients with nervous system disease. Neuroscience is the wider scientific study of the nervous system, in health as well as disease, and its practitioners are mostly researchers. The two overlap heavily in translational research.

Is neurology the same as psychiatry?

No. Both are physician specialties concerned with the brain, but neurology addresses disorders of nervous system structure and function, while psychiatry addresses mental, emotional, and behavioral disorders. Some conditions, such as dementia, are managed by both.

What does NINDS do?

NINDS is the National Institute of Neurological Disorders and Stroke, part of the NIH. It funds basic, translational, and clinical research on neurological disease, including trial networks such as StrokeNet and NeuroNEXT, and it publishes Common Data Elements for neurological research.

How long does it take to become a neurologist in the US?

After a four-year medical degree, ABPN certification requires a first postgraduate year and three years of neurology residency (or an integrated four-year program), so four years of residency in total. Subspecialty fellowships add more time. Always confirm current requirements with the ABPN.

What are common outcome measures in neurology trials?

It depends on the disease. Examples include the modified Rankin Scale and NIH Stroke Scale in stroke, the EDSS in multiple sclerosis, the MDS-UPDRS in Parkinson disease, the ALSFRS-R in ALS, and seizure frequency in epilepsy. A trial’s protocol defines exactly which are used.

Where can I find neurological trials?

Registered trials are listed on ClinicalTrials.gov, and NINDS describes its funded networks on its website. Eligibility is trial-specific and should be discussed with a qualified clinician, not decided from a registry listing.